Chronic inflammatory demyelinating polyneuropathy (CIDP ... clinical criteria and differential diagnostic exclusions are not ...

Emerging data suggest a possible genetic contributor to CIDP. In a recent study, patients with CIDP had a high frequency of perforin gene variations that impair the function of cytotoxic T and ...

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is an autoimmune disorder characterized by the progressive damage to the peripheral nerves, leading to weakness and sensory loss.

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...

Critical illness polyneuropathy (CIP) and critical illness myopathy (CIM) are major complications that occur in severely ill patients who require intensive care treatment. CIP and CIM affect the ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Suggested remit: To appraise the clinical and cost effectiveness of efgartigimod with recombinant human hyaluronidase PH20 within its marketing authorisation for treating chronic inflammatory ...

(RTTNews) - argenx SE (ARGX) announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA for adults with chronic inflammatory demyelinating polyneuropathy. VYVDURA is ...